Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Dynavax Technologies Corporation (NASDAQ: DVAX) is a commercial-stage biopharmaceutical company that develops and commercializes novel vaccines to prevent infectious diseases. The company's flagship product is HEPLISAV-B®, an adult hepatitis B vaccine. Dynavax also leverages its proprietary Toll-like Receptor 9 (TLR9) agonist adjuvant, CpG 1018®, to enhance the immune response to vaccine antigens, which is used in HEPLISAV-B and is being evaluated in other vaccine development programs, including collaborations for COVID-19 and pertussis vaccines. Their focus is on addressing unmet medical needs in infectious diseases through innovative vaccine technology.
The Emeryville headquarters serves as the central hub for Dynavax's corporate leadership, strategic planning, research and development oversight, commercial operations, finance, and administrative functions.
Located in a modern office building, the headquarters likely features contemporary office spaces designed for collaboration and may include specialized laboratory facilities or access to nearby research infrastructure, reflecting its biopharmaceutical focus.
The work culture at Dynavax's headquarters is likely dynamic, mission-driven, and scientifically focused, emphasizing innovation, collaboration, and a commitment to public health. Employees often share a passion for developing impactful vaccines.
Its location in the San Francisco Bay Area provides strategic advantages, including access to a rich talent pool, leading research institutions, venture capital, and a vibrant ecosystem of biotech companies and collaborators.
Dynavax Technologies has a focused global presence, primarily centered in North America and Europe. Its U.S. operations drive research, development, and commercialization, while its European office in Germany supports market access and commercial activities in the region. Furthermore, its CpG 1018 adjuvant is supplied globally to partners for use in various vaccine development programs, extending its impact worldwide. The company also engages in global clinical trials and collaborations to advance its pipeline.
2100 Powell Street, Suite 700
Emeryville
California
USA
Address: Graf-Adolf-Platz 15, 40213 DĂĽsseldorf, Germany
Serves as a key base for engaging with European healthcare systems, regulatory authorities, and distribution partners to expand the reach of Dynavax's vaccines in the region.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Dynavax Technologies' leadership includes:
Dynavax Technologies has been backed by several prominent investors over the years, including:
Over the past 12-18 months, Dynavax Technologies has seen some key leadership transitions aimed at strengthening its commercial and operational capabilities. Notably, there was a transition in the Chief Operating Officer role and additions to the board. Overall, the core executive team has shown stability.
Discover the tools Dynavax Technologies uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Dynavax Technologies commonly uses the email format [first_initial][last]@dynavax.com. This is a standard convention for many companies in the biopharmaceutical industry.
[first_initial][last]@dynavax.com
Format
rspencer@dynavax.com
Example
90%
Success rate
GlobeNewswire • May 7, 2024
Dynavax announced its financial results for the first quarter of 2024, highlighting HEPLISAV-B net product revenue of $50.7 million, a 17% increase year-over-year. The company reaffirmed its full-year 2024 financial guidance....more
GlobeNewswire • February 21, 2024
Dynavax reported strong financial results for Q4 and full-year 2023, driven by continued growth of HEPLISAV-B sales. The company also provided updates on its pipeline, including its plague vaccine program in collaboration with the U.S. Department of Defense....more
GlobeNewswire • January 8, 2024
Dynavax announced preliminary HEPLISAV-B net product revenue for full-year 2023, expecting it to be approximately $213 million, and provided its financial guidance for 2024, anticipating continued growth....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Dynavax Technologies, are just a search away.